OTCMKTS:VIVXF Avivagen (VIVXF) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free VIVXF Stock Alerts $0.0064 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.0064▼$0.006450-Day Range N/A52-Week Range$0.00▼$0.02VolumeN/AAverage Volume540 shsMarket Capitalization$497,216.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsShort InterestStock AnalysisChartEarningsShort Interest Get Avivagen alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Avivagen Stock (OTCMKTS:VIVXF)Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.Read More VIVXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIVXF Stock News HeadlinesApril 26, 2024 | americanbankingnews.comAvivagen Inc. (OTCMKTS:VIVXF) Short Interest Down 41.2% in AprilMarch 16, 2023 | businesswire.comAvivagen Inc. Announces Results for the First Quarter Ending January 31, 2023April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.May 30, 2022 | financialpost.comAvivagen Signs New Distribution Partner in Vietnam to Support Southeast Asian GrowthMarch 22, 2022 | financialpost.comAvivagen to Attend CEM Sponsored Alpha North ConferenceSee More Headlines Receive VIVXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avivagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)6/04/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:VIVXF CUSIPN/A CIKN/A Webwww.avivagen.com Phone613-702-2908FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,710,000.00 Net Margins-645.05% Pretax Margin-645.42% Return on EquityN/A Return on Assets-716.72% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.02 Sales & Book Value Annual Sales$730,000.00 Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-0.11Miscellaneous Outstanding Shares77,690,000Free Float76,063,000Market Cap$497,216.00 OptionableNot Optionable Beta0.12 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. G. F. Kym Anthony (Age 68)CEO & Vice Chairman Comp: $265.84kDr. Graham Burton Ph.D.Co-Founder, Chief Scientific Officer & DirectorMr. Ira LevyInterim Chief Financial OfficerDr. James Nickerson Ph.D.President and Executive VP of Business Development & Product InnovationMr. Drew BasekDirector of Investor RelationsMs. Tracy Gillett BVSCDirector of Companion Animal & Marketing ManagerMore ExecutivesKey CompetitorsGreen Organic DutchmanOTCMKTS:TGODFBZAMOTCMKTS:BZAMFSpectraScienceOTCMKTS:SCIEChina SXT PharmaceuticalsNASDAQ:SXTCBioasis TechnologiesOTCMKTS:BIOAFView All Competitors VIVXF Stock Analysis - Frequently Asked Questions How have VIVXF shares performed in 2024? Avivagen's stock was trading at $0.0006 at the beginning of the year. Since then, VIVXF shares have increased by 966.7% and is now trading at $0.0064. View the best growth stocks for 2024 here. Are investors shorting Avivagen? Avivagen saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 14,300 shares, a decline of 41.2% from the March 31st total of 24,300 shares. Based on an average daily volume of 2,000 shares, the days-to-cover ratio is currently 7.2 days. View Avivagen's Short Interest. When is Avivagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our VIVXF earnings forecast. How do I buy shares of Avivagen? Shares of VIVXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VIVXF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avivagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.